Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717942 | 0.88 | EPHX1 (0.48) | EPHX1CYP2D6CYP2C19KMT2AMGAM | |
| SCHEMBL8378421 | 0.84 | KMT2A (0.41) | EPHX1KMT2AMGAMGAASI | |
| SCHEMBL642798 | 0.83 | MTNR1A (0.43) | EPHX1KMT2AATMPIK3CGALDH1A1 | |
| SCHEMBL9397628 | 0.82 | ALDH1A1 (0.44) | EPHX1CYP2D6CYP2C19KMT2AATM | |
| SCHEMBL6360333 | 0.81 | CAPN9 (0.36) | EPHX1KMT2AATMPIK3CGPOLB | |
| SCHEMBL14240967 | 0.80 | EPHX1 (0.36) | EPHX1KMT2AATMPIK3CGPOLB | |
| SCHEMBL10008936 | 0.78 | CYP2D6 (0.50) | EPHX1CYP2D6CYP2C19KMT2AATM | |
| SCHEMBL21877077 | 0.78 | CYP2D6 (0.39) | CYP2D6CYP2C19KMT2AGAAEGLN1 | |
| SCHEMBL8940406 | 0.77 | EPHX1 (0.49) | EPHX1KMT2AATMPOLBALDH1A1 | |
| SCHEMBL20337911 | 0.77 | KMT2A (0.35) | EPHX1KMT2AATMPIK3CGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193253-A1 | SLOW-RELEASE CYTOKINE CONJUGATES | PROLYNX LLC (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2020219943-A1 | SLOW-RELEASE CYTOKINE CONJUGATES | PROLYNX LLC (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-3368093-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | Pierre Fabre Medicament (FR) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| EP-2989088-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | Pierre Fabre Médicament (FR) | 2016-03-02 | — | — | EP | disclosed |
| EP-2989087-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | Pierre Fabre Médicament (FR) | 2016-03-02 | — | — | EP | disclosed |
| EP-2989086-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | Pierre Fabre Médicament (FR) | 2016-03-02 | — | — | EP | disclosed |
| EP-2928890-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2015-10-14 | — | — | EP | disclosed |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2006028451-A1 | 1-AMINO 1-H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006026760-A2 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006018628-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1605943-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193253-A1 | SLOW-RELEASE CYTOKINE CONJUGATES | IL2, IFNG, IL6 | EPHX1 1108/4885CYP2D6 1550/4885CYP2C19 2733/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | EPHX1 4022/4885CYP2D6 2970/4885CYP2C19 2455/4885 |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | EPHX1 973/4885CYP2D6 1976/4885CYP2C19 4017/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | EPHX1 346/4885CYP2D6 40/4885CYP2C19 55/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | EPHX1 973/4885CYP2D6 1976/4885CYP2C19 4017/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | EPHX1 206/4885CYP2D6 9/4885CYP2C19 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.